Moreover, RMC-9805 combination therapies prompted regressions in CRC models that were comparatively less responsive to monotherapy.404 Additional RAS(ON) inhibitors in the company’s pipeline include RMC-0708 (KRAS Q61H), which is currently in IND-enabling development, RMC-8839 (KRAS G13C), and additional compounds targeting other RAS variants. Here, KRAS is linked to colorectal carcinoma.